PositiveID's Thermomedics
Delivers First
500 Caregiver
Bluetooth Thermometers
to Global Healthcare Company
New version of Caregiver is the first FDA
cleared non-contact, infrared thermometer
intended for professional use that utilizes Bluetooth
technology to connect wirelessly to patient
monitoring stations and electronic health records
systems
Delray Beach, FL
-- February 13, 2018 -- InvestorsHub NewsWire
-- PositiveID Corporation ("PositiveID" or "Company") (OTC:PSID),
a life sciences company focused on detection and diagnostics,
announced today that its Thermomedics subsidiary
has delivered its first 500
Bluetooth-enabled Caregiver thermometers
to a large global healthcare
customer.
Caregiver with
Bluetooth was launched in January 2018.
The new, advanced version of Caregiver is the
first FDA
cleared non-contact, infrared
thermometer intended for professional use that
utilizes Bluetooth technology to connect
wirelessly to patient monitoring stations and electronic health
records systems to transmit temperature readings
automatically into a patient's record to increase efficiency and
accuracy.
Caregiver delivers an
oral-equivalent temperature in one to two seconds
directly from the
forehead, without
contact, for adults, children, and
infants.
Since there is no skin contact and Caregiver does not require probe
cover supplies, it reduces the risk of cross-contamination, which
is an increasing concern, and saves healthcare facilities the cost
of covers (as much as $0.10 per temperature), storage space, and
waste disposal costs. It is estimated that Caregiver can offer
savings of $250 or more per year per device in probe cover supplies
alone.
"The use of wireless technology
in hospitals is becoming universal, and we believe our new version of Caregiver
with Bluetooth can help automate electronic
health records keeping for improved accuracy
and efficiency," stated Gary O'Hara, Chief
Technology Officer of Thermomedics. "We are optimistic that
as
healthcare
professionals experience the benefits of this
new version of
Caregiver, more customers will follow suit
and we will see an increase in our market share."
PositiveID believes
its next generation
Bluetooth-enabled Caregiver thermometer
holds the potential
to boost adoption of the Caregiver line to take advantage of the
growing use of infrared thermometry, which is the fastest growing
segment of the $1 billion global temperature monitoring device
market according to Global Industry
Analysts, Inc.
Caregiver is marketed by
Thermomedics, Inc., a wholly owned subsidiary of
PositiveID.
About PositiveID
Corporation
PositiveID Corporation is a
life sciences tools and diagnostics company with an extensive
patent portfolio. PositiveID develops biological detection and
diagnostics systems, specializing in the development of
microfluidic systems for the automated preparation of and
performance of biological assays. PositiveID is also a leader in
the mobile technology vehicle market, with a focus on the
laboratory market and homeland security. For more information on
PositiveID, please visit http://www.psidcorp.com, or connect with PositiveID
on Twitter, Facebook or LinkedIn.
Statements about PositiveID's future expectations, including
the likelihood that that Caregiver can offer savings of
$250 or more per year per device in probe cover supplies
alone; the likelihood that the new
version of Caregiver with Bluetooth can help automate electronic
health records keeping for improved accuracy and
efficiency; the likelihood that as healthcare
professionals experience the benefits of this new version of
Caregiver, more customers will follow suit and the
Company will see an increase in its
market share; the likelihood that the
next generation Bluetooth-enabled Caregiver thermometer holds
the potential to boost adoption of the Caregiver line to take
advantage of the growing use of infrared thermometry, which is the
fastest growing segment of the $1 billion global temperature
monitoring device market; constitute
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933, Section 21E of the Securities Exchange
Act of 1934, and as that term is defined in the Private
Litigation Reform Act of 1995. Such forward-looking statements
involve risks and uncertainties and are subject to change at any
time, and PositiveID's actual results could differ materially from
expected results. These risks and uncertainties include, without
limitation, the Company's ability to attract new customers and
retain existing customers; the Company's ability to target the
professional healthcare market; the Company's ability to raise
capital; as well as other risks. Additional
information about these and other factors that could affect the
Company's business is set forth in the Company's various filings
with the Securities and Exchange Commission, including those set
forth in the Company's 10-K filed on March 31, 2017, and 10-Qs
filed on November 13, 2017, August 14, 2017,
and May 15, 2017, under the caption "Risk Factors."
The Company undertakes no obligation to update or release any
revisions to these forward-looking statements to reflect events or
circumstances after the date of this statement or to reflect the
occurrence of unanticipated events, except as required by
law.
Contact:
PositiveID
Corporation
Allison Tomek
(561) 805-8044
atomek@psidcorp.com